INVA Innoviva Inc.

14.49
+0.06  (+0%)
Previous Close 14.43
Open 14.3
Price To Book 5.49
Market Cap 1,467,533,710
Shares 101,279,069
Volume 576,442
Short Ratio
Av. Daily Volume 631,023
Stock charts supplied by TradingView

NewsSee all news

  1. Innoviva Reports Third Quarter 2019 Financial Results

    Total net revenue increased by 7% to $65.8 million in the third quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 15% to $57.6 million in the third quarter of 2019,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced April 24, 2018 for expanded label.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approval announced September 18, 2017.
Trelegy Ellipta (FF/UMEC/VI)
Chronic obstructive pulmonary disease (COPD)
sNDA filing announced October 2, 2019.
Closed Triple - CAPTAIN
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD

Latest News

  1. Innoviva Reports Third Quarter 2019 Financial Results

    Total net revenue increased by 7% to $65.8 million in the third quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 15% to $57.6 million in the third quarter of 2019,